Search

Researchers from Tongji University in Shanghai, China have developed a new treatment for osteoporosis that combines two existing therapies to improve efficacy. The treatment involves the use of a carrier-free dual-medication nanoassembly made of antiresorptive alendronate (ALN) crystal and antisclerostin polyaptamer (Apt). This nanoassembly protects the Apt from degradation, concentrates in the cancellous bone, and releases the drugs in response to the acidic microenvironment of the bone. The study demonstrates the potential of nucleic acid-driven crystallization for the development of targeted therapies for various diseases. [Extracted from the article]

Researchers at the University of Ha'il in Saudi Arabia have used artificial intelligence (AI) to model the solubility of the medication Alendronate. By inputting temperature and pressure parameters, the researchers evaluated three different models, with the AdaBoost model showing the highest performance. The research concluded that using this ensemble method, the root mean square error rate was 4.30E-02 and the mean absolute error was 2.96E-02. This study demonstrates the potential of AI in optimizing drug solubility and improving therapeutic effectiveness. [Extracted from the article]

A study conducted by Harvard University examined the effectiveness of different durations of antiresorptive therapy following the discontinuation of denosumab, a medication used to treat osteoporosis. The study found that 12 months of alendronate therapy was able to maintain the bone mineral density gains achieved with denosumab. The researchers also observed that both 1 and 2 years of alendronate effectively maintained these gains and prevented any rebound in bone turnover marker levels. The study suggests that these findings may be helpful in guiding clinical care for patients. Further research is needed to determine optimal management after longer durations of denosumab. [Extracted from the article]

A study conducted by researchers at Harbin Medical University in China has developed a novel drug for the treatment of osteoporosis with fewer side effects. The drug, called ALEN-CDs, is derived from polyethylene glycol and alendronate and has shown good biocompatibility and bone-targeting ability. It inhibits the differentiation and maturation of osteoclasts and regulates the bone immune microenvironment by affecting mitochondrial metabolism. In vivo studies on mice have demonstrated that ALEN-CDs significantly reduce bone loss and improve osteoporosis. The researchers conclude that ALEN-CDs may be a promising drug for the treatment of osteoporosis. [Extracted from the article]

A study conducted by researchers at Kermanshah University of Medical Sciences in Iran has developed a nanofiber membrane for guided periodontal tissue and bone regeneration. The membrane was fabricated using electrospinning techniques and was evaluated for its in vivo performance and biocompatibility. The researchers found that the membrane showed suitable characteristics for use in promoting bone regeneration and had a sustained release of alendronate sodium, a drug that inhibits the accumulation of osteoclasts. This research provides new insights into tissue engineering and could have implications for the treatment of periodontitis. [Extracted from the article]

Researchers from Fuji Yakuhin Company Co. Ltd. in Saitama, Japan have conducted a study on bone resorption and calcification. They found that bisphosphonates, a type of drug, have inhibitory effects on both calcium-phosphate aggregation and bone resorption, making them potential anti-calcifying drugs. The researchers used animal models to examine the effects of three bisphosphonates on bone resorption and calcium-phosphate aggregation. They concluded that models with low bone resorption, such as the lead acetate-induced model, may be ideal for extrapolating the calcifying response to humans. This research has been peer-reviewed. [Extracted from the article]

A recent report from the Ruder Boskovic Institute in Zagreb, Croatia, explores the use of alendronate as a bioactive coating on titanium surfaces for dental implants. The study found that the deposition of calcium phosphate on the alendronate-modified titanium surface is facilitated by interactions between calcium ions and phosphonate groups, as well as hydrogen bonding. The research highlights the spontaneous formation of calcium phosphate on the alendronate-coated titanium surface, confirming the bioactivity of the coating. These findings have implications for the development of biomaterials and surface modification of dental implants. [Extracted from the article]

Researchers at Fudan University in Shanghai have published a study on bone cement and its potential for bone regeneration. The study focuses on the treatment of osteoporotic bone defects, which can be challenging to heal due to an imbalance between osteogenesis and osteoclastogenesis. The researchers developed a high-strength bone cement that promotes osteogenic differentiation and neovascularization while inhibiting osteoclastogenesis. In an in vivo model, the injection of this cement significantly improved bone healing. The study concludes that this injectable cement shows promise as a treatment for osteoporotic bone defects. [Extracted from the article]

A recent study conducted by researchers at the National University of Quilmes in Buenos Aires, Argentina, explores the use of cholesterol nanoarchaeosomes for targeted delivery of the drug alendronate as an anti-endothelial dysfunction agent. Alendronate is a molecule used to treat bone loss and has potential anti-inflammatory properties. The researchers found that the endocytosis of nanoarchaeosomes loaded with alendronate enhanced its anti-inflammatory activity, surpassing that of free alendronate and dexamethasone. This study provides valuable insights into the potential use of targeted nanovesicles for treating vascular endothelial dysfunction. [Extracted from the article]

A recent study conducted by researchers at the Federal University of Pernambuco in Brazil has found a potential genetic association between the farnesyl diphosphate synthase (FDPS) gene and the response to alendronate sodium treatment in patients with primary osteoporosis. The study analyzed the FDPS variant rs2297480 (A > C) and its association with treatment response in 304 osteoporosis patients. The researchers observed that the CC genotype of the variant was associated with treatment failure and a decrease in bone mineral density after two years of alendronate sodium treatment. The study suggests that a genetic approach may be important in improving the efficacy of treatment for primary osteoporosis. [Extracted from the article]

A recent report from Ferdowsi University of Mashhad in Iran discusses research on tissue engineering for the treatment of osteoporosis. The researchers aimed to develop printable materials for the construction of patient-specific 3D scaffolds with drug-release capability. The scaffolds, composed of chitosan, nanohydroxyapatite, sodium alendronate, and hydroxyethyl-cellulose, demonstrated biocompatibility and sustained release of alendronate for 50 days. The study suggests that these printable materials have potential applications as cell and drug carriers for the treatment of osteoporosis. [Extracted from the article]

Researchers from Tarbiat Modares University in Tehran, Iran have published a new report on tissue engineering. The study focuses on the optimization of natural polymers, such as silk fibroin, gelatin, and alginate, as bioink for 3D bioprinting in bone tissue engineering. The researchers found that the addition of silk fibroin improved the physicochemical properties of the bioink, while higher alginate concentration increased the compressive modulus. Through parameter optimization, the researchers achieved the highest print accuracy with 4% w/v alginate content. The printed scaffolds exhibited both macro and micro porosity, making them suitable for bone tissue regeneration. The study also found that the bioink demonstrated excellent biocompatibility and enhanced alkaline phosphatase activity in osteoblast-like cells when supplemented with alendronate. Overall, the study successfully optimized the bioink and bioprinting process for bone tissue engineering applications, showing promising potential for future advancements in the field. [Extracted from the article]

A recent study conducted by researchers at the Faculty of Dental Medicine has found that patients with osteoporosis have a higher risk of developing periodontitis. The study investigated the impact of systemic alendronate, a drug used to treat osteoporosis, on periodontal parameters in osteoporosis and periodontitis patients. The results showed that oral administration of alendronate for 12 months improved the outcomes of non-surgical periodontal therapy, suggesting that it could be a valuable adjunctive treatment for managing periodontal disease in osteoporotic patients. This research provides important insights into the relationship between osteoporosis and periodontitis and offers potential treatment options for patients. [Extracted from the article]

A recent study conducted by researchers at Shanghai Jiao Tong University School of Medicine has explored the potential use of ultrasmall gold particles loaded with alendronate, a commonly used drug for osteoporosis, in the treatment of the disease. The study found that these gold particles, coated with alpha-lipoic acid, were able to promote bone density and prevent bone loss in osteoporotic mice. The particles showed no evidence of toxicity and could potentially be used as a targeted therapy for osteoporosis in the future. This research provides new insights into the development of treatments for metabolic bone diseases using Angstrom-scale gold particles. [Extracted from the article]

A recent study conducted at Monash University in Melbourne, Australia, examined the effect of drug holidays on postfracture mortality in patients with extended use of oral bisphosphonates. The study found that postfracture mortality was higher in patients who had discontinued risedronate for 1 or 2 years prior to hip fracture, but no increase or decrease in postfracture mortality was observed in patients who had discontinued alendronate. The researchers suggest that the type of bisphosphonate may be a factor to consider when planning drug holidays. This information may be useful for individuals considering the use of oral bisphosphonates and their healthcare providers. [Extracted from the article]

A recent study conducted by researchers at Nanchang University in China has developed a new nanomedicine for the treatment of osteoporosis. The nanomedicine, called HQPA, is pH-responsive and bone-targeted, and it demonstrated dual anti-osteoporosis effects in vitro by promoting osteoblasts and inhibiting osteoclasts. In addition, HQPA was found to effectively reduce bone loss in mice without causing significant toxicity to major organs. The researchers believe that this method could be a useful approach for developing nanomedicines for the treatment of various bone-related diseases. [Extracted from the article]

A recent study conducted by researchers at Tel Aviv University explored the therapeutic potential of S-Allylmercapto-N-Acetylcysteine (ASSNAC) in treating osteoporosis in ovariectomized (OVX) mice. The study found that ASSNAC, an activator of nuclear factor erythroid 2-related factor 2 (Nrf2) and a supplier of cysteine, prevented bone loss in the mice after four weeks of treatment. Additionally, the combination of ASSNAC and Alendronate, a commonly used medication for osteoporosis, further augmented the bone-protective effect. The study suggests that ASSNAC has potential as a therapeutic option for post-menopausal osteoporosis and may also ameliorate the oxidative stress associated with Alendronate treatment. [Extracted from the article]

Researchers from Universitas Sebelas Maret conducted a study to evaluate the effects of alendronate and platelet-rich plasma (PRP) on tendon-to-bone integration in anterior cruciate ligament (ACL) surgery. The study used sheep as experimental animals and divided them into four groups: a control group, a group given PRP, a group given alendronate, and a group given both PRP and alendronate. The researchers found that the administration of alendronate and PRP improved the healing of tendon-calcaneal ACL reconstruction surgery in sheep. The study provides valuable insights into potential treatments for poor integration of tendons with bone in ACL reconstruction. [Extracted from the article]

A recent study conducted by researchers at the I.R.C.C.S. Santa Lucia Foundation in Rome, Italy, explored the safety and efficacy of calcifediol and cholecalciferol in combination with alendronate for osteoporotic women. The study involved 300 postmenopausal osteoporotic women, with half receiving alendronate combined with calcifediol and the other half receiving alendronate combined with cholecalciferol. The results showed that calcifediol was as safe as cholecalciferol and more effective in increasing vitamin D serum levels after four and 12 months of supplementation. The study concluded that calcifediol could be a beneficial option for osteoporotic women undergoing therapy with alendronate. [Extracted from the article]

A recent study conducted at Jagiellonian University in Krakow, Poland, has explored the use of injectable hydrogel-based materials for the delivery of alendronate, a drug used in the treatment of osteoporosis. The researchers developed multifunctional hybrids composed of mesoporous silica particles loaded with alendronate and immobilized in a collagen/chitosan/hyaluronic acid-based hydrogel. The study found that the materials were safe for blood elements and human liver cells, promoted the differentiation of bone marrow stem cells, and reduced the viability of osteoclast precursors. The researchers concluded that these composites have the potential to be a safe and effective therapy for osteoporosis. [Extracted from the article]

A recent report from Ferdowsi University of Mashhad in Iran discusses a study on osteoporosis. The researchers conducted an in-situ synthesis of a coating containing an osteoporosis drug on an AZ31 magnesium alloy substrate. Various characterization techniques were used to analyze the coating, which showed enhanced hydrophilicity, improved corrosion resistance, and reduced porosity. The study also found sustained drug release and progressive biodegradation of the coating. The research concluded that kinetic control was the rate-controlling step in the electrochemical interface. This study provides valuable insights into the development of coatings for osteoporosis treatment. [Extracted from the article]

A study conducted by researchers at Radboud University Nijmegen in the Netherlands examined the cytocompatibility of a bone adhesive biomaterial called POx-Ale. The study evaluated the effects of POx-Ale on various cell types relevant to bone reconstructive surgery, including pre-osteoblasts, fibroblasts, and pre-osteoclasts. The results showed that POx-Ale had cytotoxic effects on these cell types at certain concentrations, inhibiting mineralization of osteoblasts and MMP activity of fibroblasts. However, it did not negatively affect Tartrate-resistant acid phosphate (TRAP) activity in osteoclasts. This research provides valuable insights into the potential use of POx-Ale as a bone fixation biomaterial. [Extracted from the article]

A recent study conducted at Ningbo Medical Center Lihuili Hospital in China investigated the effectiveness of denosumab combined with alendronate and nutritional intervention on bone metabolism and density in postmenopausal patients with osteoporosis. The study found that patients who received this combination therapy had lower levels of certain bone markers, higher bone densities in the lumbar and femoral neck, lower pain scores, and a lower fracture rate compared to those who received sodium phosphate and nutrition intervention therapy alone. The study concluded that denosumab combined with alendronate and nutritional intervention is a safe and effective approach for improving bone health in postmenopausal patients. [Extracted from the article]

A study conducted at the Second Hospital of Jilin University in Changchun, People's Republic of China, has explored a new strategy for regenerating bone defects caused by osteoporosis. The researchers used short fibers loaded with alendronate modified hydroxyapatite to overcome the challenges of overactive bone resorption and limited bone formation. The modified fibers showed good cytocompatibility and promoted the activity of alkaline phosphatase, extracellular matrix mineralization, and the expression of osteogenesis-related genes. In vivo experiments demonstrated that the fibers accelerated new bone formation, inhibited bone resorption, and rebalanced the bone microenvironment. The study suggests that these short fibers have potential applications in bone tissue scaffolds. [Extracted from the article]

Researchers at Tarbiat Modares University in Tehran, Iran have developed nanoparticles for targeted drug delivery to improve the effectiveness of chemotherapy on osteosarcoma, a type of bone cancer. The nanoparticles, made from silk fibroin and sodium alginate, were decorated with sodium alendronate to actively target the tumor site. The nanoparticles showed higher drug release at acidic pH and demonstrated effectiveness in bone targeting. The study concluded that these nanoparticles hold promise as a potential drug delivery system for osteosarcoma treatment. [Extracted from the article]

A patent has been issued for fluoro beta-carboline compounds by Ossifi Therapeutics LLC. The compounds and compositions described in the patent can be used to treat various bone disorders, fractures, and related issues. The invention aims to stimulate osteoblast cells to increase bone mineral deposition, which can improve bone density and promote healing. The patent provides specific formulas for the compounds and includes claims for different forms and compositions. This information may be useful for researchers and individuals interested in bone health and stem cell research. [Extracted from the article]

New research from the New Mexico Clinical Research & Osteoporosis Center has found that romosozumab treatment in women with postmenopausal osteoporosis can increase bone formation and decrease bone resorption, resulting in significant gains in bone mineral density (BMD) within one year. The study used 3D modeling from hip DXA scans to assess changes in bone parameters over time in patients from two clinical trials. The results showed that treatment with romosozumab led to greater increases in BMD, cortical thickness, and trabecular BMD compared to placebo or alendronate. These findings suggest that romosozumab can improve hip bone density and structure, contributing to its effectiveness in preventing fractures. [Extracted from the article]

This document provides information about a clinical trial, NCT06264609, that is currently underway at the University of Kentucky. The trial aims to address the treatment of osteoporosis, a health problem that affects a significant number of Americans and leads to numerous fractures each year. The study focuses on age-related bone loss, which is often overlooked in current therapies, and aims to compare the effectiveness of two drugs, Alendronate and Teriparatide, in treating osteoporosis based on bone turnover. The trial is enrolling female participants aged 45 and older who have been diagnosed with osteoporosis. The study is ongoing and is expected to be completed by December 31, 2029. [Extracted from the article]

Researchers at the University of Eastern Piedmont in Italy have conducted preliminary studies on the use of alendronate-grafted nanoemulsions for bone-targeted vincristine delivery. The study aims to develop pharmacological therapies for malignant tumors that cause distant metastases in the bone. The researchers found that alendronate conjugation enhanced the bone targeting of the nanoemulsions in animal models. These promising results will lead to further studies on suitable animal models of the disease. [Extracted from the article]

A recent study conducted by researchers from Shanghai Jiao Tong University in China has explored the potential of a novel therapeutic agent for osteoporosis. The study investigated the use of strontium-doped mesoporous bioactive glass loaded with alendronate as an alternative treatment to alendronate alone. The findings suggest that this new agent, called ALN@Sr-MBG, displays enhanced biological efficacy in terms of inflammation inhibition, osteogenesis promotion, and osteoclastogenesis inhibition. Animal models also showed that ALN@Sr-MBG significantly improved bone mineral density and reduced bone resorption compared to alendronate alone. The study concludes that ALN@Sr-MBG has the potential to be a promising alternative therapy for osteoporosis. [Extracted from the article]

A new report from Peking University Cancer Hospital in Beijing, China, discusses research on apoptosis, a form of cell death. The study focuses on the challenges faced by conventional chemotherapy in light of advancements in monoclonal antibodies and targeted drugs. The researchers propose a new approach using bisphosphonate coordination lipid nanogranules (BC-LNPs) loaded with paclitaxel (PTX) to enhance the effectiveness of cytotoxic drugs. By inhibiting mevalonate metabolism, the BC-LNPs@PTX trigger a form of cell death called ferroptosis, which remodels the tumor immune microenvironment and synergizes with immunotherapy. This research provides new insights into the development of cytotoxic drugs and highlights the potential of metabolism regulation in cancer therapy. [Extracted from the article]

A recent study conducted by Sorbonne University in Bobigny, France, has revealed new findings on drug delivery systems for bone-targeted therapies. The researchers focused on the synthesis of alendronate analogs, which are commonly used in the treatment of bone disorders. The study aimed to develop alendronate derivatives with tunable functions on their side chain, allowing for improved drug delivery to bone tissue. The research provides valuable insights into the development of more effective drug delivery strategies for bone-related conditions. [Extracted from the article]

A recent report from the University of Hong Kong discusses the development of magnesium-organic framework-loaded bisphosphonate-functionalized gel scaffolds for enhanced bone regeneration. The researchers aimed to address the limitations of magnesium-derived biomaterials and alendronate, a drug used for osteoporosis treatment, in bone tissue engineering. By combining magnesium-metal-organic frameworks and bone-targeting alendronate with biocompatible gelatin scaffolds, the researchers created nanocomposite gel scaffolds that exhibited excellent biocompatibility, slow release of magnesium and alendronate, and strong bone affinity. The scaffolds also promoted osteogenic differentiation and improved bone regeneration. This research has potential implications for bone regenerative medicine. [Extracted from the article]

Researchers at the University of Science and Technology China have developed a drug-mineralized hydrogel (DMH) that mimics the dynamic mineralization process of natural tissues. The DMH is created by mixing sodium hyaluronate (HA) with alendronate sodium (ADA) and calcium chloride (CaCl2) in water. The hydrogel undergoes a spontaneous dynamic mineralization process, transforming from a soft gel to a hard mineral structure over time. The DMH demonstrates sustained release of ADA and shows promise for accelerating bone repair. This research provides a general strategy for preparing drug-mineralized hydrogels with dynamic mineralization behaviors, which could have various biomedical applications. [Extracted from the article]

A recent study conducted by researchers at the Universitat Autonoma de Barcelona in Spain compared the cost-effectiveness of two treatments for postmenopausal osteoporosis (PMO): weekly gastro-resistant risedronate 35 mg tablets (RIS-GR) and weekly alendronate 70 mg tablets (ALN). The study found that treatment with RIS-GR resulted in a lower cost per patient and a gain in quality-adjusted life years (QALYs) compared to ALN. RIS-GR was also associated with a reduced risk of fractures. These findings suggest that RIS-GR may be a more beneficial and cost-effective treatment option for PMO. [Extracted from the article]

A recent study conducted at Yunnan University in Kunming, China, has reported promising results regarding the use of alendronate-derived carbon dots (Alen-CDs) for bioimaging and osteoblastic differentiation induction. Alen-CDs are a type of nanomaterial that have shown good biocompatibility and fluorescent properties. The study found that Alen-CDs were effective for in vitro fluorescent imaging without toxicity and also promoted the survival and differentiation of rat bone marrow mesenchymal stem cells. These findings suggest that Alen-CDs could be used as a potential probe for bioimaging and as a nanodrug for bone regeneration. [Extracted from the article]

A recent study conducted by researchers at the Tokyo Institute of Technology has explored the use of alendronate therapy for accelerated fracture healing. The researchers developed a modified form of alendronate called PEG-ALN, which efficiently delivers the active ingredient to fracture sites. In experiments conducted on mice, PEG-ALN was found to selectively accumulate at the fracture site and significantly accelerate bone healing compared to free ALN. This study suggests that PEG-ALN could be a promising systemically injectable medicine for patients with bone fractures. [Extracted from the article]

Researchers from Sun Yat-sen University in Guangdong, China have developed a new material for bone regeneration in osteoporosis. The material, called alendronate-decorated strontium-containing bioactive glass nanoparticles (A-SrBG), has shown promising results in promoting the differentiation of osteoblasts and inhibiting the differentiation of osteoclasts. The A-SrBG nanoparticles were able to induce apatite mineralization and release bioactive ions, and when implanted in vivo, they promoted the regeneration of new bone. This research suggests that A-SrBG nanoparticles could be a potential candidate for reconstructing bone defects in osteoporosis. [Extracted from the article]

A recent study conducted by researchers from the University of Palermo in Italy explored the impact of bone modifying agents (BMAs) on secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors (AIs). The study compared the effects of alendronate and denosumab on bone mineral density (BMD) and pain levels in these patients. The results showed that both alendronate and denosumab significantly improved BMD at the lumbar spine level, but had no significant effect on the femoral region. Alendronate also had a significant impact on pain control. The study suggests that alendronate may be a cost-effective option for preventing secondary osteoporosis and managing pain in this patient population. [Extracted from the article]

A recent study conducted at King Abdulaziz University in Jeddah, Saudi Arabia, explored the use of a nanoemulsion-based injectable in-situ gel formulation for the management of osteoporosis. The researchers aimed to prevent bone resorption in rats by combining a phospholipid-based phase separation in-situ gel with an alendronate sodium nanoemulsion. The study found that the optimal nanoemulsion formulation resulted in sustained and regulated release of alendronate sodium, leading to a higher percentage of the drug remaining in the rats' muscles after 30 days compared to the conventional oral form. This research suggests that the nanoemulsion-based injectable in-situ gel may be a promising platform for the treatment of osteoporosis. [Extracted from the article]

A recent study conducted by researchers at the University Magna Graecia of Catanzaro has provided new insights into the effects of alendronate therapy on human periodontal ligament stem cells (hPDLSCs). Alendronate is a commonly used bisphosphonate for treating osteoporosis and cancer-induced bone lesions. The study found that high concentrations of alendronate led to a decrease in cell viability and impaired mobility of hPDLSCs. Additionally, chronic exposure to alendronate resulted in a decrease in the expression of differentiation-related factors and the osteogenic ability of hPDLSCs. The findings suggest a potential role for oxidative stress in alendronate-induced cell death and may contribute to the development of new therapeutic approaches for osteonecrosis of the jaws (ONJ). [Extracted from the article]

Researchers from Iran University of Science and Technology have conducted a computational analysis of drug release from metal-organic frameworks (MOFs), specifically UiO-66, which are recognized as nanocarriers due to their structure and porosity. The study focused on the release patterns of three drugs: temozolomide, alendronate, and 5-fluorouracil. The findings suggest that UiO-66 has potential as a nanocarrier for drug delivery, and the research provides insights into the dynamics of drug release and the factors influencing it. This work contributes to the understanding of UiO-66's role and could lead to improved cancer treatment. [Extracted from the article]

A recent report discusses research on tissue engineering conducted at China Medical University. The study focuses on the development of nanofiber scaffolds enriched with hydroxyapatite (HA) nanoparticles and alendronate (ALN) using the electrospinning technique. The results show successful fabrication of the scaffolds and their physicochemical properties, including hydrophilicity and biodegradability. The scaffolds also demonstrated non-toxic and biocompatible behavior, promoting osteoblast activity and inhibiting osteoclast activity. Overall, the study suggests that these nanofiber composite scaffolds hold promise for bone regeneration applications. [Extracted from the article]

Researchers at Shaare Zedek Medical Center in Jerusalem have made new findings in cancer gene therapy. They have developed a formulation called PLAD, which co-encapsulates the drugs Doxorubicin and Alendronate in pegylated liposomes. This formulation has shown significant immune modulatory effects and distinct tumor microenvironmental interactions, making it a potential candidate for chemo-immunotherapy of cancer. The researchers believe that the co-encapsulation approach in nanomedicine has added value in enhancing the therapeutic effects of these drugs. [Extracted from the article]

A recent study conducted at Rush University Medical Center in Chicago, Illinois, examined the treatment patterns of osteoporosis medications. The study analyzed data from 12,885 patients who received bisphosphonates, denosumab, raloxifene, or teriparatide for osteoporosis over a 10-year period. The findings revealed that alendronate was the most common initial treatment, followed by ibandronate and raloxifene. Denosumab was the most common second course of treatment prescribed. The study also observed a decline in osteoporosis therapy over the duration of the study. [Extracted from the article]

A recent study conducted by researchers at Tokyo Medical and Dental University (TMDU) has found that alendronate, a drug commonly used to treat bone loss, can be effective in treating a specific form of Paget's disease called early-onset Paget's disease of bone with PFN1 mutation. The study used a mouse model to evaluate the efficiency of alendronate in treating bone loss and skeletal deformities associated with this disorder. The results showed that alendronate significantly improved bone mass and normalized osteoclasts in the mice. The researchers concluded that preventive treatment with alendronate could be a feasible option for managing bony deformities in early-onset Paget's disease. [Extracted from the article]

Researchers at Harvard University conducted a study to compare the efficacy of alendronate and raloxifene in preventing bone loss after discontinuing denosumab. The study involved 51 postmenopausal women at risk of fracture who were randomly assigned to receive either alendronate or raloxifene for 12 months after denosumab treatment. The results showed that alendronate was better at maintaining the inhibition of bone remodeling and bone mineral density gains compared to raloxifene. These findings suggest that alendronate may be a more effective treatment option in this context. The study has been peer-reviewed and published in Osteoporosis International. [Extracted from the article]

A study conducted at Aarhus University Hospital in Denmark investigated the effectiveness of buffered and effervescent alendronate (ALN-EFF) compared to conventional alendronate (ALN) in suppressing bone turnover markers (BTM). The study included 64 postmenopausal women and found that there was no significant difference in the suppression of BTMs between the two groups. However, the study was unable to establish formal non-inferiority. The research suggests that ALN-EFF may be a potential alternative to ALN for osteoporosis treatment, but further research is needed. [Extracted from the article]